NuVasive Stock News

Continued strong international performance and introduction of products drove NuVasive's (NUVA) revenues in the fourth quarter of 2021.

Continued strong international performance and introduction of products drove NuVasive's (NUVA) revenues in the fourth quarter of 2021.

NuVasive (NUVA) delivered earnings and revenue surprises of -14.89% and 1.50%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

NuVasive press release (NUVA): Q4 Non-GAAP EPS of $0.40 misses by $0.35.Revenue of $302.08M (+3.5% Y/Y) misses by $15.54M.FY 2022 Guidance: Revenue growth to be in the range…

SAN DIEGO, Feb. 23, 2022 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced financial results for the quarter and full year ended…

NuVasive, Inc. (NUVA) CEO Chris Barry on Q4 2021 Results - Earnings Call Transcript

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Kodiak's Wet AMD Treatment KSI-301 Did Not Meet Primary Endpoint In Phase 2b/3 Study Kodiak Sciences

NuVasive (NASDAQ:NUVA) is scheduled to announce Q4 earnings results on Wednesday, Feb. 23, after market close.The consensus EPS estimate is $0.75 (+27.1% Y/Y)

Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front, the Food and Drug A

Pune, Feb. 17, 2022 (GLOBE NEWSWIRE) -- " Final Report will add the analysis of the impact of COVID-19 on this industry. " Global " Spinal Implants and Surgery Devices Market " is a comprehensive research that provides information regarding Spinal Implants and Surgery Devices market size, trends, growth, cost structure, capacity, revenue, and forecast for 2027. This report also includes the overall study of the Spinal Implants and Surgery Devices Market share with all its aspects influencing the growth of the market. This report is exhaustive quantitative analyses of the Spinal Implants and Surgery Devices industry and provides data for making strategies to increase Spinal Implants and Surgery Devices market growth and effectiveness. The report further investigates and assesses the current landscape of the ever-evolving business sector and the present and future effects of COVID-19 on the Spinal Implants and Surgery Devices market. The global Spinal Implants and Surgery Devices market size is projected to reach US$ 13440 million by 2027, from US$ 9529.7 million in 2020, at a CAGR of 5.0% during 2021-2027.

New York, USA, Feb. 16, 2022 (GLOBE NEWSWIRE) -- Global Orthobiologics Market is Anticipated to Grow at a CAGR of 4.44% During the Forecast Period (2021-26) | DelveInsight As per DelveInsight analysis, a growing geriatric population at risk of developing various bone degenerative disorders, an increase in traumatic injuries such as car accidents, sports injuries, and others are expected to boost the Orthobiologics market growth. Furthermore rising investments in R&D and collaborations by key manufacturers, as well as an increase in various orthobiologic product approvals will also drive the market. DelveInsight''s Orthobiologics Market Insights and Forecast report provides the current and forecast Orthobiologics market, upcoming developments in the medical devices, individual market shares, challenges, drivers, barriers, market growth trends, and key players in the Orthobiologics market. Some of the Key Highlights from the Orthobiologics Market Report According to DelveInsight analysis, North America is expected to dominate the overall Orthobiologics Market during the forecasted period.

NuVasive Inc. (NASDAQ:NUVA)s traded shares stood at 0.39 million during the last session, with the companys beta value hitting 1.17. At the close of trading, the stocks price was $50.59, to imply a decrease of -1.75% or -$0.9 in intraday trading. The NUVA shares 52-week high remains $72.61, putting it -43.53% down since that peak NuVasive Inc. (NASDAQ: NUVA): Can A Stock Be Down -3.60% YTD, And Still Be A Loser Read More »

SAN DIEGO, Feb. 8, 2022 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, announced today the Company will release its fourth quarter and full year…

SAN DIEGO, Feb. 8, 2022 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integra